Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC. van Grunsven Jasper reported acquisition or exercise transactions in this Form 4 filing.
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported that executive vice president Jasper van Grunsven received an award of 8,682 shares of common stock on September 8, 2026, as a stock-based compensation grant at no cash purchase price.
The award is in the form of restricted stock units that vest in installments beginning on September 8, 2027. After this grant, he is reported as directly holding 8,682 common shares. No transactions were reported under a Rule 10b5-1 trading plan.
VERTEX PHARMACEUTICALS INC / MA (VRTX) filed an initial statement of beneficial ownership for Jasper van Grunsven, who serves as EVP, CP and NPPO. The Form 3 lists no reportable holdings or transactions in Vertex securities at the time of this filing. A Power of Attorney is noted as Exhibit 24.
VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC.
VERTEX PHARMACEUTICALS INC / MA (VRTX) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027, while Charles F. Wagner, Jr. will remain Executive Vice President and Chief Operating Officer. Poole has served as Senior Vice President, Finance at Vertex since March 2020 and previously held CFO roles at several biotechnology companies.
Under his new employment agreement, Poole will receive a $750,000 base salary and a target annual bonus of 90% of base salary. If terminated without cause or he resigns for good reason, he is entitled to cash severance equal to 100% of base salary and target bonus, plus any earned but unpaid prior-year bonus, subject to a release. A separate change of control agreement provides for similar cash benefits, a pro‑rated target bonus, payment of other earned incentives, and full vesting of outstanding equity awards upon qualifying terminations around a change of control, plus up to 12 months of Company-paid medical, dental, and life insurance premiums if COBRA coverage is elected.
VERTEX PHARMACEUTICALS INC / MA (VRTX) director Bruce I. Sachs reported a disposition of common stock through a bona fide gift. On 2026-08-27, he transferred 6,000 shares of Vertex common stock, recorded at $0.00 per share for reporting purposes, and reported holding 39,000 shares directly afterward.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a notice of proposed sale filed for shares of its common stock under Rule 144. Director Bruce I. Sachs plans to sell 1,210 shares of Vertex common stock through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $662,535.50. The shares were acquired as a gift and are held jointly with Kimberlie T. Sachs as JTWROS. As of this notice, 253,460,924 shares of Vertex common stock were outstanding, and the shares are listed on NASDAQ. The remark states that shares are sold through the Watercove Charitable Foundation, where Bruce I. Sachs serves as trustee.
Vertex Pharmaceuticals reported strong Q2 2026 results, with total revenues of $3.33 billion versus $2.96 billion a year earlier and first‑half revenues of $6.32 billion versus $5.73 billion. Net income was $1.10 billion for the quarter and $2.13 billion year‑to‑date, with diluted EPS of $4.31 and $8.33, respectively. Growth was driven by cystic fibrosis therapies overall, particularly ALYFTREK, and expanding contributions from CASGEVY and JOURNAVX, while TRIKAFTA/KAFTRIO revenue declined modestly.
Income from operations reached $1.25 billion in Q2. Cost of sales rose to 14.7% of net product revenue, reflecting product mix. R&D spending was stable at $1.96 billion for the first half, while SG&A increased to $582.2 million in Q2 and $1.08 billion year‑to‑date as the company invested in new product launches. Operating cash flow strengthened to $2.55 billion in the first half.
Liquidity remains significant, with $13.64 billion in cash, cash equivalents and marketable securities and working capital of $8.61 billion as of June 30, 2026. Vertex repurchased 1.8 million shares for $799.5 million in the first half and has $2.6 billion remaining under its 2025 repurchase program. Strategically, it agreed to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, backed by a new $4.5 billion term loan facility and a $500 million revolving credit facility, both currently undrawn, while also addressing an arbitration over ALYFTREK royalty rates.
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion, up 12% year over year, driven by cystic fibrosis products and growing contributions from CASGEVY and JOURNAVX. GAAP net income was $1.10 billion (diluted EPS $4.31); non-GAAP net income was $1.21 billion (EPS $4.73).
Cash, cash equivalents and marketable securities totaled $13.6 billion as of June 30, 2026, reflecting strong operating cash flow partially offset by share repurchases. The company raised full-year 2026 revenue guidance to $13.1–$13.2 billion, embedding expectations for $0.5 billion or more of non-CF product revenue.
Vertex highlighted rapid uptake of CASGEVY and JOURNAVX, an FDA PDUFA date of November 30, 2026 for IgAN drug povetacicept, and an agreement to acquire Crinetics Pharmaceuticals for about $10.0 billion, adding a rare endocrine disease portfolio.
Vertex Pharmaceuticals reported a compensation-related equity grant to EVP and Chief Regulatory & Quality Officer Ourania Tatsis. She acquired 8,251 shares of common stock in the form of a restricted stock unit award on 07/21/2026, vesting on 03/31/2030, bringing her direct holdings to 53,572 shares.
Vertex Pharmaceuticals executive Amit Sachdev reported an acquisition of 8,251 shares of common stock on 2026-07-21 through a restricted stock unit award that vests on 03/31/2030. Following this award, he holds 66,512 shares directly, plus 882 shares indirectly via a 401(k) and 6,637 shares held in trust.